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Abstract
This study complies with the reorganization of health care provider processes based on the cost of life cycle of the
product. The aim is to determine the costs of treatment administration of extracorporeal dialysis and other treatments
in extracorporeal systems.
The strategy here was to apply for the first time the “bill of material” (BoM) method to the production and management
of the services above.
By using standard replacement flows, we build the “bill of materials” to calculate the cost of a CRRT (continuous renal
replacement therapy) with anticoagulant. The standard cost of the process is thus obtained.
The method here developed can be used for accounting purposes and for economic planning, as a tool for accurate
statistical evaluation of medical care.
Keywords: Bill of materials, Continuous renal replacement therapy, Regional anticoagulation, Citrate, Cost of life cycle
Introduction
This paper provides a method to determine the costs of
treatment administration of extracorporeal dialysis and
other treatments in extracorporeal systems, from a citrate
CRRT treatment, proposed by the industry, and from
another regional anticoagulation realized using heparin,
protamine hydrochloride, and epoprostenol previously
reported by Fabbri et al. [1], and here called HPE. The two
methods are comparable because the anticoagulant
strategy is limited to the extracorporeal circuit (regional
anticoagulation), representing a key issue for safe and
effective RRT (renal replacement therapy). HPE and simi-
lar (without citrate) methods were recently reviewed by
Brophy et al. [2], by considering benefits and drawbacks,
including circuit lifespan. The anticoagulant allows to
easily reach the target of 72 h of treatment as explained by
the device technical documentation.
In this context, the present study allows one to thor-
oughly address a budget target concerning the monitoring
of overall expenditure for procurement and management
decisions. In this way, the study can provide a guideline to
calculate the life-cycle costs of the product, in agreement
with the European legislation about public procurement,
see [3]. Health system public procurement is generally
based on the economically most advantageous tender. On
the other hand, for the recent European directive, see [3],
a new criterion was introduced based on the life-cycle cost
as it considers also environmental and/or social aspects.
In our study, we proved that three equivalent techniques
imply different overall costs in terms of circuit life, waste
management, personnel costs, etc.
Cost analysis starts when the machine is ready for
usage with the appropriate medical devices and stops at
waste management.
In the literature, several studies have developed cost
analysis related to such treatments, starting from the
cost of consumables and human resources required for
their administration (see, e.g., [4]). The costs are calcu-
lated with time references differing from study to study.
Fluid, dialysate, and reinfusion liquid consumption are
usually calculated taking into account average flows,
while the variability of the reinfusion liquid flows upon
varying solute concentration is neglected.
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On the other hand, some analyses, like [5], demon-
strate that flows are actually extremely variable, fact
that determines a high-cost variability, which is also
due to different work organization. Other studies focus
on the trend of the human resource costs, which vary
considerably with work organization and treatment
administration procedure (see, e.g., [6]).
Hence, it follows that the results of the various studies
are hardly comparable among themselves since the diffi-
culty of accurately identify the real contribution of each
raw material to the treatments remains. Indeed, to the
very best of our knowledge, the standard cost of such
treatments has never been calculated so far. For this
reason, it is not possible to make a factual comparison
between the prices of the treatments as a whole, but it is
only possible to make a comparison between single parts.
The economic crisis of the last 10 years has led us to
take into account not only the clinical outcome, but also
the economic one, especially in treating patients of the
critic care, whose cost represents one of the most rele-
vant items of expenditure in the health sector, as in [7].
The literature shows that also QALYs (Quality-Adjusted
Life Year) studies (see, e.g., [8, 9]) must not disregard a
thorough cost analysis and a research of production
processes that are able to reduce them, so that the
choice of the methodology may go back to being primar-
ily of clinical type, as in [10–12].
The purpose of the present paper is to provide a
method for analyzing standard costs correlated to the
product life cycle, i.e., of treatment administration,
according to [3]. The use of citrate as an anticoagulant
has been wide-spreading since 2010, it can be used as a
base for a number of other treatments but its cost
depends on several variables which make it difficult to
determine with acceptable accuracy.
Materials and methods
Description of materials used
All the materials are referred to 2015 technology. The
following materials are employed for the entire treatment:
1) Infusion bags and dialysate: 5-L bags including all
formulations on the market at the same price range.
The dialysate bags are without calcium.
2) Bags with 10 L effluent for the citrate system with a
flow equal to 200 mL/h–bags with 9 L effluent for
citrate system with a flow equal to 2250 mL/h: for
the calculation of costs, the average price among
those of the purchase procedure is used.
3) 2-L bags with citrate concentration of 136 mmol
Na3/L for the system citrate flow equal to 200
mL/h–5 L citrate bags with a concentration of
12 mmol Na3/L for the citrate system with a flow
equal to 2250 mL/h: for the calculation of costs
the average price among those of the purchase
procedure is used.
4) HPE: replacement bags and dialysate bags 5 L;
effluent bags 10 L; heparin 25,000 I.U./5 mL vial;
protamine hydrochloride 50 mg/5 mL vial at the
dosage of 1 mg/100 I.U. Heparin; epoprostenol 0.5
mg plus 50 mL diluent
5) Kit with lines, filter, junctions (joints, fittings): for
the calculation of costs, the average price among
those of the purchase procedure is used.
6) Monitors in usage.
Model description
In order to calculate the actual cost of each treatment,
we used the method of BoM (bill of materials) to iden-
tify all the components, sub or intermediate assemblies,
raw materials, parts, and quantities of what is needed to
carry out the treatment, determining the impact for each
of them in the production process.
We built the BoM of a treatment in CRRT with citrate
in CVVHDF (continuous venovenous hemodiafiltration)
mode, proposed by the industry, and in CRRT with hep-
arin, protamine, and epoprostenol in CVVHDF mode. We
assume, as usual, the examined treatment at zero level,
and at least the most important components at level 1.
We can build simpler basic bills or more complex
ones for the analysis of the most appropriate cost.
Determining the flows of substitution allows one to
calculate the duration in minutes of each bag/vial used
and, as a consequence, the number of bags/vials re-
quired to produce the considered treatment, compared
to the duration of the treatment itself.
Flow replacements are parametrized using the ones
most frequently programmed in the dialysis monitor.
We call them “standard flows” following [13–15], and
the related costs “standard costs.”
In Table 1, we report the values for the treatment
with citrate and the same values are shown for the
HPE method.
Table 1 Prescribed dose for a treatment in CRRT in CVVHDF
mode with anticoagulant
FLOW DESCRIPTION CVVHDF
Qb Blood flow 150mL/min
Cp Weight loss 100 mL/h
Qd Dialysate flow 1300 mL/h
Qinf Replacement fluid flow (pre-post) 2000 mL/h
Qef Effluent flow 3400 mL/h
QNa3 Citrate flow mL/h To be determined
Qe Heparin diluted flow 1000 UI/h
Qpr Protamine diluted flow 10 mg/h
Qp Prostacyclin diluted flow (epoprostenol) 20,000 ng/h
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For the flow of fluids during CRRT treatments, a
number of variables must be taken into account, related
to the use of the therapeutic dose established by the
operator according to the different types of patient. To
this regard, we must consider that the prescribed dose
can vary from 20 to 35 up to 43mL/kg/h of effluent
representing any exchange of fluids and the weight loss
set. The dose, however, should never be less than 35mL/
kg/day, whichever mode you choose, CVVHD (continu-
ous venovenous hemodialysis), CVVH (continuous
venovenous hemofiltration), CVVHDF dividing the
infusion rate in pre-and post-dilution as required by the
operator based on the type of patient. When using the
therapeutic dose of 43 mL/kg/h, in the more complex
form of CRRT, the CVVHDF, the portions of infusion
fluids are generally distributed as follows: 25 mL/kg/h
for the fluids to re-infusion and 18 mL/kg/h for the
dialysate. Even for the lower doses, the ratio between
convective and diffusive portion is about 60/40.
It should be noted, however, that there must be a
verification of the dose prescribed and that actually pro-
vided. In theory, if there were no errors or changes the
value of the effluent measured by the monitor should
match that one expected. In fact, during the CRRT, there
is always downtime related to the operations of the nurs-
ing staff estimated in the table of costs in 72 h.
When the Qef value is used, as defined in Table 1, the
citrate flow variable must be added, once it is determined.
The amount of citrate to be infused is assumed equal
to 3 mmolNa3/L of blood.
Once blood flow is established and given the concen-
tration of citrate bag expressed in mmol Na3/L, the
citrate flow is determined by the linear relationship:
Qb mL/h: n. mmol di Na3/L/h = Q Na3 mL/h: 3 mmol
Na3/L/h.
The industry proposes 2-L bags with a concentration
equal to 136 mmol Na3/L and 5 L bags with concentra-
tion equal to 12 mmol Na3/L/h.
The proportion determines a value of QNa3 equal to
200 mL/h in the former case, and a value of QNa3 equal
to 2250 mL/h, in the latter.
The total Qef therefore will vary from Qef = 3600mL/
h to Qef = 5650mL/h:
Qef + QNa3 = 200 mL/h (with Qef = 3600mL/h)
Qef + QNa3 = 2250 mL/h (with Qef = 5650mL/h)
We are now able to compute the coefficients of use
of the bags or vials for 24 h and then for 72 h of
treatment (Table 2).
The coefficients to use for medical devices for 72 h
are equal to one unit each, for all types of consid-
ered treatment.
The coefficients needed for the equipment can be
calculated, for all the different types of considered treat-
ments, on the basis of the estimate of the average
number of treatments performed each year. The follow-
ing formula was used:
C = (V/8)/N
where C is the equipment cost for each treatment,
V is the market value of the equipment offered in the
tender, to be amortized over 8 years,1 N is the
number of treatments/year per equipment. The coeffi-
cient of utilization of the monitor is V/8N. V includes
the cost of maintenance and technical assistance. Re-
garding the cleaning of the circuit, this is carried out
before each treatment with a washing solution in the
extracorporeal blood circuit 2-L bag.
Electricity consumption is estimated by the equip-
ment’s service manual. Unit costs of electric power
and wastes were taken from the power supply and
waste disposal contracts, respectively valid at the time
of the present study. Staff and laboratory tests costs
were provided by the management control system of
health authorities. Average unit costs were determined
by the management control system according to costs
analytical accounting.
Among the coefficients related to the management of
the process, for all the types of the considered treatment,
the interventions of personnel for the exchange-bags/
vials, is estimated equal to 5 min, plus additional 5 min
for each laboratory test. During the treatments proposed
by the industry, an average of 14 laboratory tests are
performed: these are tests of blood gas analysis,
performed at the beginning of the treatment, after 5 min,
after 3 h and then one every 6 h. During all the types of
treatments in HPE, an average of four laboratory tests
are performed: these are complete coagulation tests.
The amount of liquid waste is given by the remainder
in the infusion bags, dialysate, citrate if infused, plus
replacement fluids consisting of the decrease in weight
of 7.2 L in 72 h. In case of a QNa3 = 200 mL/h treatment,
the replacement fluid is 260 L (actually, 93.9 L + 144 L +
14.4 L + 7.2 L = 259.5 L).
This is likely due to approximations of calculation. The
error, however, is believed to be negligible. The same
applies to the QNa3 = 2250mL/h treatment, for which the
calculated discrepancy is equal to 720mL in 72 h.
The solid wastes were weighed at the end of each
type of treatment: 100 g for empty 5-L bag and 200 g
for empty 9 or 10-L bag; the empty kit for the QNa3 =
200 mL/h treatment is 1.600 kg, and 1.150 kg for the
QNa3 = 2250 mL/h treatment.
In CRRT in CVVHDF mode with HPE,
anticoagulant-related wastes are not present.
Results
The standard costs can be calculated using the con-
tract prices, noted by the sign “€”.2 Electric power
supply cost is estimated to be 0.17 €/KW. Personnel
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cost has been estimated with the aid of the manage-
ment control. It was calculated as the average cost
comprehensive of allowance and related obligations,
and resulted to be equal to 0.38 €/min. The cost of
laboratory analyses is the same as calculated by the
management control. Waste disposal costs are esti-
mated to be 1.00 €/L or kg. The costs are summa-
rized in Tables 3 and 4.
The total costs of replacement fluids of medical
devices and equipment are not significantly different for
the three methods and therefore they can be considered
constant in these three cases.
The cost difference between the two methodologies
proposed by the industry is due to the number of citrate
bags necessary for the treatment. Such variable in turn
depends on solute concentration (citrate, in this case)
with respect to the therapeutic dose. The solute concen-
tration is an important variable that might be standard-
ized (see [16]) with respect to the therapeutic doses in
order to contribute to consumption and cost reduction.
In the case of HPE, the cost of the anticoagulant is re-
lated to the costs of the components used in the treatment.
Process costs are highly correlated to the different
methods of regional anticoagulant.
This or a similar method should be applied to calcu-
late the life-cycle costs, every time a medical device re-
quires consumable material.
In order to extend the cost analysis, the major
out-of-process parameters affecting the average/standard
cost of the treatment were also taken into account.3
It is known that the lifetime of the filter has a major
impact on the overall costs due to the possibility of filter
clotting, which in turn determines further out-of-process
costs which can be calculated thanks to the BoM. In fact,
in such circumstance, the treatment has to be discontin-
ued, patient taken off the machine, bags and filter
disposed of the new circuit has to be assembled, washed
with priming solution, and connected to the patient to re-
sume the treatment.
Circuit lifetime was estimated from Gattas et al. [17]
in the case of citrate and from Fabbri et al. [1] in the
case of HPE.
From Kaplan-Meier estimate in [17], the probability
p = 0.25 for the circuit survival for the whole duration of
the treatment (72 h) was inferred. In the case when no
filter clotting occurs (p = 0.25) the citrate treatment cost,
as calculated with the BoM, averaged over the two dif-
ferent infusion flow rates (QNa3 = 2250 mL and QNa3 =
200 mL/h), as proposed by the industry, is C = 1525.12€.
In the complementary clotting scenario,4 whose
occurrence has probability 1-p = 0.75, out-of-process
costs to be considered are 1 dialysate bag, 1 replace-
ment bag, 1 Na3 bag, 1 effluent bag, 1 filter/equip-
ment; costs of disposal of replaced bags (this can be
determined only when knowing the clotting time t);
personnel costs, 50 min.
Considering the above extra-costs, the total out-
of-process costs: COoP = 174.38 €. Therefore, the cost
increases by 11.4%.
In total, the overall mean value cost weighted on the
two scenarios, according to the given probability p, is
equal to
p  C þ 1−pð Þ  C þ COoPð Þ ¼ 1655:90 €
Considering instead HPE treatment, we have,
according to [1], that the probability for the circuit sur-
vival for the whole duration of the treatment is p = 0.40.
We have C = 1270.82 €, with a total out-of-process
costs COoP = 160.46 €, amounting to a cost increase of
12.6%. Therefore, the overall mean value cost weighted
on the two scenarios, according to the given probability
p, is equal to
p  C þ 1−pð Þ  C þ COoPð Þ ¼ 1367:10 €
We developed dynamic spreadsheets to be filed for
each patient, taking into account the actual flows and
actual therapeutic doses, which may vary during 72 h of
Table 2 Number of bags per 24 h treatments CRRT in CVVHDF mode with citrate and with HPE
Treatments in CVVHDF with anticoagulant Utilized components Minute duration bags or vials
(bag’s volume/infusion flow)
Bags per 24 h
Dialysate bags without Ca 5 L 230min n. 6.26
Replacement bags 5 L 150min n. 9.6
Na3 bags 2 L with 136 mmol Na3/L 600 min n. 2.4
Na3 bags 5 L with 12 mmol Na3/L 132 min n. 10.9
Effluent bags at Qef = 5650 mL/h 95min n. 15.16
Effluent bags at Qef = 3600 mL/h 166min n. 8.67
Heparin vial 25,000 UI 1500min n. 0.96
Protamine vial 250 mg 1500min n. 4.8
Epoprostenol prostacyclin vial 500,000 ng 1500min n. 0.96
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treatment. In this way, it is possible to accurately predict
and calculate real-time consumption and the cost of the
active productive process and collect the data needed to
implement an appropriate statistical analysis.
Discussion
During the fulfillment of our contract, we submitted our
BoMs to three suppliers; these BoMs were based on stand-
ard flows, taking into account only the consumables.
They were asked to determine the citrate flow starting
from the therapeutic infusion dose, 3 mmol QNa3/
blood/L. The suppliers are therefore taking part in the
expense control phase. Their answers were compared
with our results. One supplier provided data in agree-
ment with the ones expected for 7 methods out of 7.
Another supplier provided the data expected for 7
methods out of 9, and underestimated data for 2
methods: the mismatch is due to the fact that QNa3
values lower than actual ones were declared. The third
supplier failed to provide any data for 2 methods out of
2, stating that the costs were not determinable.
These results confirmed the correctness of the
method. The method was however further checked by a
medical-scientific and an engineering point of view.
Moreover, further investigations concerning the produc-
tion process discussed above were carried out. These
deeper controls led us to conclusions that could not be
drawn from the simpler BoM, submitted to suppliers.
For instance, it can be inferred that in CRRT treatments
with citrate, the concentration of the solution in the bag
obviously importantly affects the quantity of the bags
needed and therefore on personnel costs, the liquid
waste produced and on the standard cost.
Conclusion
Precise identification of real contribution of each raw
material to the treatments makes it possible to estimate
exactly the cost of the product life cycle. Such transpar-
ency can guide the medical activity, as well as the choices
of the industry and the public buyer. The clinicians may
include in their choices considerations about personnel
management, easiness, and readiness of laboratory
analysis and waste disposal. Since the BoM takes into
account all the costs detailed above, it may be an efficient
tool to guide the internal activities of the suppliers who, in
turn, may invest in research and development to obtain
more efficient BoMs to submit to the public service [16].
Such types of analyses allow the suppliers to enter the
process supply chain and take advantage of their own
ability in competitive cost reduction.
The public buyer is able to predict, quantify, and
justify higher than expected expenses.
Lastly, BoM provides a valuable tool for the assess-
ment of the supply quality, quantifying qualitative
aspects, otherwise difficult to measure and compare. In
this way, determining standard costs would be an asset
for all the health productive processes.
Endnotes
1At the time of the tender, Italian legislation
established 8 years term as depreciation rate for
electromedical devices, that is 12.5% per annum of the
market value (Decreto Ministero dell’Economia e delle
Finanze, 31 dicembre 1988).
2Detailed costs proposed by the industry are consid-
ered confidential data and therefore not fully disclosable.
3Unit costs of electric power, laboratory tests, and
wastes are determined by long-term (10 years) contracts;
therefore, they can be considered constant during the
considered period. Staff contracts are renegotiated every
10 years.
4For simplicity, the adverse complementary scenario
considers the occurrence of a single clotting.
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